Pompe disease

Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs their ability to function normally.

Researchers have described three types of Pompe disease, which differ in severity and the age at which they appear. These types are known as classic infantile-onset, non-classic infantile-onset, and late-onset.

The classic form of infantile-onset Pompe disease begins within a few months of birth. Infants with this disorder typically experience muscle weakness (myopathy), poor muscle tone (hypotonia), an enlarged liver (hepatomegaly), and heart defects. Affected infants may also fail to gain weight and grow at the expected rate (failure to thrive) and have breathing problems. If untreated, this form of Pompe disease leads to death from heart failure in the first year of life.

The non-classic form of infantile-onset Pompe disease usually appears by age 1. It is characterized by delayed motor skills (such as rolling over and sitting) and progressive muscle weakness. The heart may be abnormally large (cardiomegaly), but affected individuals usually do not experience heart failure. The muscle weakness in this disorder leads to serious breathing problems, and most children with non-classic infantile-onset Pompe disease live only into early childhood.

The late-onset type of Pompe disease may not become apparent until later in childhood, adolescence, or adulthood. Late-onset Pompe disease is usually milder than the infantile-onset forms of this disorder and is less likely to involve the heart. Most individuals with late-onset Pompe disease experience progressive muscle weakness, especially in the legs and the trunk, including the muscles that control breathing. As the disorder progresses, breathing problems can lead to respiratory failure.

Frequency

Pompe disease affects about 1 in 40,000 people in the United States. The incidence of this disorder varies among different ethnic groups.

Causes

Mutations in the GAA gene cause Pompe disease. The GAA gene provides instructions for producing an enzyme called acid alpha-glucosidase (also known as acid maltase). This enzyme is active in lysosomes, which are structures that serve as recycling centers within cells. The enzyme normally breaks down glycogen into a simpler sugar called glucose, which is the main energy source for most cells.
Mutations in the GAA gene prevent acid alpha-glucosidase from breaking down glycogen effectively, which allows this sugar to build up to toxic levels in lysosomes. This buildup damages organs and tissues throughout the body, particularly the muscles, leading to the progressive signs and symptoms of Pompe disease.

Inheritance Pattern
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition
- acid maltase deficiency
- acid maltase deficiency disease
- alpha-1,4-glucosidase deficiency
- AMD
- deficiency of alpha-glucosidase
- GAA deficiency
- glycogen storage disease type II
- glycogenosis Type II
- GSD II
- GSD2
- Pompe's disease

Diagnosis & Management
Genetic Testing Information
- What is genetic testing?
  /primer/testing/genetictesting
- Genetic Testing Registry: Glycogen storage disease type II, infantile
- Genetic Testing Registry: Glycogen storage disease, type II

Research Studies from ClinicalTrials.gov
- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22Glycogen+Storage+Disease+Type+II%22+OR+%22Pompe+disease%22
Other Diagnosis and Management Resources

- Baby's First Test
  https://www.babysfirsttest.org/newborn-screening/conditions/pompe
- GeneReview: Pompe Disease
  https://www.ncbi.nlm.nih.gov/books/NBK1261
- National Organization for Rare Disorders (NORD) Physician Guide
  https://rarediseases.org/physician-guide/pompe-disease/

Additional Information & Resources

Health Information from MedlinePlus

- Health Topic: Carbohydrate Metabolism Disorders
  https://medlineplus.gov/carbohydratemetabolismdisorders.html

Genetic and Rare Diseases Information Center

- Glycogen storage disease type 2

Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Myopathy Information Page
  https://www.ninds.nih.gov/Disorders/All-Diseases/Myopathy-Information-Page
- National Institute of Neurological Disorders and Stroke: Pompe Disease Information Page
  https://www.ninds.nih.gov/Disorders/All-Diseases/Pompe-Disease-Information-Page

Educational Resources

- MalaCards: neurological manifestations of pompe disease
  https://www.malacards.org/card/neurological_manifestations_of_pompe_disease
- Merck Manual Consumer Version: Overview of Hereditary Metabolic Disorders
- Orphanet: Glycogen storage disease due to acid maltase deficiency
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=365

Patient Support and Advocacy Resources

- Acid Malate Deficiency Association
  http://www.amda-pompe.org/
- Association for Glycogen Storage Disease
  https://www.agsdus.org/type-ii.php
Clinical Information from GeneReviews

- Pompe Disease
  https://www.ncbi.nlm.nih.gov/books/NBK1261

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Glycogen+Storage+Disease+Type+II%5BMAJR%5D%29+AND+%28%28glycogen+storage+disease+type+II%5BTIAB%5D%29+OR+%28pompe%5BTIAB%5D%29+OR+%28acid+maltase+deficiency%5BTIAB%5D%29+OR+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- GLYCOGEN STORAGE DISEASE II
  http://omim.org/entry/232300

Sources for This Summary


• Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D; Infantile-Onset Pompe Disease 
Natural History Study Group. A retrospective, multinational, multicenter study on the natural history 
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16737883

• Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, 
Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson 
MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS. Pompe disease diagnosis and 
382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to 
Case, Laura E]. 
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16702877 
Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110959/

• van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, 
Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT. The natural course of infantile Pompe's 
disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003 Aug; 
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12897283

• van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008 Oct 11;372(9646):1342-53. doi: 
10.1016/S0140-6736(08)61555-X. Review. 
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18929906

Reprinted from Genetics Home Reference: 

Reviewed: February 2016
Published: January 29, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services